注册 | 登录
点击这里给我发消息
所有产品
  • 所有产品
  • 一抗
  • 裂解液
>   首页   >   产品   >   一抗   >   其他   >   EVER2 Antibody   

EVER2 Antibody

     
  • 1 - EVER2 Antibody ASC10692
    Western blot analysis of EVER2 in Jurkat cell lysate with EVER2 antibody at (A) 1 and (B) 2 µg/mL.
  • 2 - EVER2 Antibody ASC10692
    Immunohistochemistry of EVER2 in human brain with EVER2 antibody at 5 µg/mL.
  • 3 - EVER2 Antibody ASC10692
    Immunofluorescence of EVER2 in Human Brain cells with EVER2 antibody at 20 µg/mL.
  • 产品详情
  • 实验流程
  • 背景知识
Product Information
Application
  • Applications Legend:
  • E=ELISA
  • WB=Western Blotting
  • IHC=Immunohistochemistry
  • IHC-P=Immunohistochemistry (Paraffin)
  • IP=Immunoprecipitation
  • IF=Immunofluorescence
  • IC=Immunochemistry
  • ICC=Immunocytochemistry
  • FC=Flow Cytometry
  • DB=Dot Blot
WB, IF, E, IHC-P
Primary Accession Q8IU68
Other Accession AAM44454, 25527192
Reactivity Human, Mouse, Rat
Host Rabbit
Clonality Polyclonal
Isotype IgG
Calculated MW 81641 Da
Concentration (mg/ml) 1 mg/mL
Conjugate Unconjugated
Application Notes EVER2 antibody can be used for detection of EVER2 by Western blot at 1 - 2 µg/mL. Antibody can also be used for immunohistochemistry starting at 5 µg/mL. For immunofluorescence start at 20 µg/mL.
Additional Information
Gene ID 147138
Other Names Transmembrane channel-like protein 8, Epidermodysplasia verruciformis protein 2, TMC8, EVER2, EVIN2
Target/Specificity TMC8; At least three isoforms of EVER2 are known to exist; this antibody will only recognize the larger isoform. EVER2 has no cross-reactivity to EVER1.
Reconstitution & Storage EVER2 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
PrecautionsEVER2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.
Protein Information
Name TMC8 (HGNC:20474)
Function Acts as a regulatory protein involved in the regulation of numerous cellular processes (PubMed:18158319, PubMed:23429285, PubMed:30068544, PubMed:32917726). Together with its homolog TMC6/EVER1, forms a complex with calcium-binding protein CIB1 in lymphocytes and keratynocytes where TMC6 and TMC8 stabilize CIB1 levels and reciprocally (PubMed:30068544, PubMed:32917726). Together with TMC6, also forms a complex with and activates zinc transporter ZNT1 at the ER membrane of keratynocytes, thereby facilitating zinc uptake into the ER (PubMed:18158319). Also inhibits receptor-mediated calcium release from ER stores and calcium activated and volume regulated chloride channels (PubMed:25220380). Down-regulates the activity of transcription factors induced by zinc and cytokines (PubMed:18158319). Also sequesters TRADD which impairs the recruitment of TRAF2 and RIPK1 in the pro-survival complex I and promotes proapoptotic complex II formation, and may therefore be involved in TNF-induced cell death/survival decisions (PubMed:23429285).
Cellular Location Endoplasmic reticulum membrane; Multi-pass membrane protein. Golgi apparatus membrane; Multi-pass membrane protein. Nucleus membrane; Multi-pass membrane protein. Note=Localizes to the ER, Golgi and nucleus membranes in keratinocytes.
Tissue Location Expressed in placenta, prostate and testis.
Research Areas

For Research Use Only. Not For Use In Diagnostic Procedures.

BACKGROUND

EVER2 Antibody: Epidermodysplasia verruciformis (EV) is an autosomal recessive genodermatosis associated with a high risk of skin cancers resulting from a high susceptibility to infection by specific human papillomaviruses. Mutations in two homologous genes EVER1 and EVER2 cause the majority of EV cases. These two proteins form a complex and interact with the zinc transporter ZnT-1 in the endoplasmic reticulum. Cells lacking EVER2 accumulated higher levels of zinc in the nucleolus and nucleus compare to those cells with and intact EVER2 gene, indicating that one role of EVER2 is to regulate the intracellular distribution of zinc.

REFERENCES

Ramoz N, Taieb A, Rueda L-A, et al. Evidence for a nonallelic heterogeneity of epidermodysplasia verruciformis with two susceptibility loci mapped to chromosome regions 2p21-p24 and 17q25. J. Invest. Dermatol.2000; 114:1148-53.
Ramoz N, Rueda L-A, Bouadjar B, et al. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat. Genet.2002; 32:579-81.
Lazarczyk M, Pons C, Mendoza J-A, et al. Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses. J. Exp. Med.2008; 205:35-42.

FeedBack

终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。

如有疑问,联系:0512-88856768 tech-china@abcepta.com.


我要评价